Randall B. Brenner Net Worth

The estimated Net Worth of Randall B. Brenner is at least $1.63 Milhão dollars as of 8 August 2023. Mr Brenner owns over 27,603 units of Paratek Pharmaceuticals stock worth over $925,916 and over the last 5 years he sold PRTK stock worth over $703,895.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Brenner PRTK stock SEC Form 4 insiders trading

Mr has made over 14 trades of the Paratek Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 27,603 units of PRTK stock worth $60,727 on 8 August 2023.

The largest trade he's ever made was selling 29,282 units of Paratek Pharmaceuticals stock on 12 December 2022 worth over $57,686. On average, Mr trades about 9,456 units every 74 days since 2019. As of 8 August 2023 he still owns at least 415,209 units of Paratek Pharmaceuticals stock.

You can see the complete history of Mr Brenner stock trades at the bottom of the page.

Mr. Randall B. Brenner biography

Randall B. Brenner is the Chief Devel. & Regulatory Officer at Paratek Pharmaceuticals.

How old is Mr Brenner?

Mr Brenner is 48, he's been the Chief Devel. & Regulatory Officer of Paratek Pharmaceuticals since . There are 12 older and 3 younger executives at Paratek Pharmaceuticals. The oldest executive at Paratek Pharmaceuticals Inc. is Sergey Guz, 64, who is the Independent Director.

What's Mr Brenner's mailing address?

Randall's mailing address filed with the SEC is C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON, MA, 02116.

Insiders trading at Paratek Pharmaceuticals

Over the last 10 years, insiders at Paratek Pharmaceuticals have traded over $9,410,794 worth of Paratek Pharmaceuticals stock and bought 1,743,576 units worth $13,751,429 . The most active insiders traders include James D Dondero, Bioventures Cayman Ltd Hbm, eEvan Loh. On average, Paratek Pharmaceuticals executives and independent directors trade stock every 24 days with the average trade being worth of $63,310. The most recent stock trade was executed by Randall B. Brenner on 8 August 2023, trading 27,603 units of PRTK stock currently worth $60,727.

What does Paratek Pharmaceuticals do?

paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.

Complete history of Mr Brenner stock trades at Paratek Pharmaceuticals

Paratek Pharmaceuticals executives and stock owners

Paratek Pharmaceuticals executives and other stock owners filed with the SEC include:

• Dr. Evan Loh FACC, FAHA, M.D.,
  CEO & Director
• Dr. Evan Loh,
  CEO & Director
• Michael F. Bigham CPA, CPA, M.B.A., MBA,
  Exec. Chairman
• Michael F. Bigham CPA, M.B.A., CPA, MBA,
  Exec. Chairman
• Adam Woodrow,
  Pres & Chief Commercial Officer
• Leonid Sevastyanov,
  Independent Director
• Sergey Guz,
  Independent Director
• Aleksandr Sukhoruchenko,
  Director
• Vadim Gorbunov,
  Director
• Yuliya Yakunina,
  Director, Director of Economics
• Timofey Prokopov,
  Vice President for Finance and Investment
• Anna Kinash,
  Chief Accountant
• Vadim Muzyaev,
  President, Deputy Chairman of the Board
• Vadim Yakunin,
  Chairman of the Board, Adviser to President
• Randall B. Brenner,
  Chief Devel. & Regulatory Officer
• Karen McGrath,
  Sr. VP of HR
• Christine R. Coyne M.B.A.,
  VP of Marketing
• Ben Strain,
  VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
• Jason Burdette,
  Sr. VP of Technical Operations
• Sarah Higgins,
  VP, Controller and Interim Principal Financial & Accounting Officer
• William M. Haskel,
  Sr. VP, Chief Legal Officer, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Michael Bigham,
  Exec. Chairman of the Board
• Fund Iii, L.P.Omega Fund Iv...,
  
• Douglas W. Pagan,
  Chief Financial Officer
• Thomas John Dietz,
  Director
• Robert S Radie,
  Director
• Richard J. Lim,
  Director
• Timothy R Franson,
  Director
• Jeffrey Stein,
  Director
• Kristine Peterson,
  Director
• William M. Haskel,
  CLO, General Counsel & Sec.
• Evan Loh,
  CEO
• Randall B. Brenner,
  Chief Development & Regulatory
• Kathryn M. Boxmeyer,
  See Remarks
• Bioventures Cayman Ltd Hbm,
  10% owner
• Rolf K Hoffmann,
  Director
• Minnie Baylor Henry,
  Director
• James D Dondero,
  10% owner